March 6 (Reuters) - Wegovy maker Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health platform, bringing an end to a dispute between the two companies that escalated into a legal ...

The 2013 declaration of obesity as a chronic disease and the 2021 approval of semaglutide are associated with increased use ...

New data showed childhood obesity has hit a record high in recent years, while federal changes such as cuts to food assistance programs and a revamped food pyramid reignite debates over how to handle ...

In recent years, rates of childhood obesity have been rising, with the U.S. Centers for Disease Control estimating in 2024 ...

Postmenopausal obesity increases ER-positive breast cancer risk, particularly in non-HRT users, while premenopausal overweight may lower risk.

Today is World Obesity Day, a day dedicated to shining a spotlight on one of the most pressing health crises of our time. It ...

Childhood obesity is usually associated with unhealthy food and too little physical activity. For this reason, many health initiatives focus on improving diet and increasing physical activity. However ...

Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking one part of the Big Biotech’s differentiated play for the obesity market.

This article first appeared on GuruFocus. Hims & Hers Health (NYSE:HIMS) shares jumped sharply on Monday following reports that Novo Nordisk (NYSE:NVO) may distribute its obesity drugs to HIMS through ...

Hims & Hers Health Inc. surged after Novo Nordisk A/S was said to have ended its public feud with the company with an agreement to sell its weight-loss drugs on the Hims platform.

Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity treatment benefits and costs.

Technology assistance reduces some complications, but could make infections more likely ...